Clinical trials: Major Depression Mild
Restless Legs Syndrome, Moderate to Severe Idiopathic Restless Legs Syndrome (RLS)
The Effects Of Ropinirole On Mood Or Mild Depression In Patients With Moderate To Severe Restless Legs Syndrome
Ropinirole has shown to improve mood in depressed patients as well as to improve the symptoms of Restless Legs Syndrome. Up to 40% of RLS patients suffer from mild depression, therefore it would be important for decisions no…
- Trial name
- NCT00357097
- Testing
- Ropinirole
- Where
- 50 sites in Germany
- Volunteers
- 240 people
- Sponsor
- GlaxoSmithKline
Depressive Disorder, Major Depressive Disorder
Study of Virtual Reality-based Medical Device for Patients with Depressive Disorder
This study apply a wearable visual device (HMD)-VR-based software medical device for patients with depressive disorder for 8 weeks.
- Conditions
- Depressive Disorder, Major Depressive Disorder, Depressive Episode
- Trial name
- NCT05701345
- Testing
- OMNIFIT DTx-MDD, standard treatment
- Where
- 5 sites in South Korea
- Volunteers
- 162 people
- Sponsor
- Omni C&S
Depression, Depression Moderate
Kintsugi Voice Device Pivotal Study
A prospective, single arm, non-randomized, pivotal clinical validation study to evaluate the ability of the Kintsugi Voice Device (the Device) to aid clinical assessment for depression by comparing its output with a diagnosis…
- Conditions
- Depression, Depression Moderate, Depression Severe, Depression Mild
- Trial name
- NCT06809907
- Testing
- Kintsugi Voice Device
- Where
- United States
- Volunteers
- 1,600 people, healthy volunteers welcome
- Sponsor
- Kintsugi Mindful Wellness, Inc.
Hepatic Impairment
Pharmacokinetics of AGO178 in Participants With Liver Impairment
AGO178 was developed for the treatment of depression. A new formulation is being tested in the present study: a tablet to be placed and dissolved under the tongue (sublingual tablet).
- Trial name
- NCT01531309
- Testing
- AGO178
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Mild to Moderate Depression
Management Strategy for Mild to Moderate Major Depression: Combination of Rhodiola and Saffron Extracts.
The purpose of the study is to describe, over 6 weeks, the evolution of depressive symptoms in patients with mild to moderate major depression in a strategy with Phytostandard® Rhodiola-Saffron supplementation
- Trial name
- NCT02981225
- Testing
- Phytostandard® Rhodiola-Saffron
- Where
- France
- Volunteers
- 59 people
- Sponsor
- PiLeJe
Major Depressive Disorder (MDD)
Evaluation of the Concordance Between Measures Obtained by a Medical Device for Emotional Monitoring (EMOCARE) and the Patient Health Questionnaire (PHQ-9) Score in Patients With Mild to Severe Depressive Episode
The aim of this clinical investigation is to find out whether the EMOCARE emotional monitoring software provides consistent results compared with the tools available for assessing the emotional state of patients suffering from…
- Trial name
- EMC1 (NCT06601140)
- Testing
- EMOCARE software
- Where
- 11 sites in France
- Volunteers
- 104 people
- Sponsor
- Emobot
Depression, Depression Moderate
Kintsugi Voice Device Pilot Study
A prospective, single arm, non-randomized, pilot clinical validation study to evaluate the ability of the Kintsugi Voice Device (the Device) to aid clinical assessment for depression by comparing its output with a diagnosis made…
- Conditions
- Depression, Depression Moderate, Depression Severe, Depression Mild
- Trial name
- NCT06374056
- Testing
- Kintsugi Voice Device
- Where
- United States
- Volunteers
- 262 people, healthy volunteers welcome
- Sponsor
- Kintsugi Mindful Wellness, Inc.
Depressive Episode, Depression
Sleep Signal Analysis for Current Major Depressive Episode (SAMDE)
The objective of this study is to collect data to finalize the development of MEB-001 software as a medical device. The data collected in this study will be used to develop MEB-001 machine learning algorithms by training the…
- Conditions
- Depressive Episode, Depression, Depressive Disorder, Depressive Disorder, Major
- Trial name
- SAMDE (NCT05708222)
- Testing
- MEB-001
- Where
- 13 sites in United States
- Volunteers
- 715 people
- Sponsor
- Medibio Limited
Depression
The Efficacy and Safety of tDCS in Patients With Mild to Moderate Major Depressive Disorder
This study evaluated the effectiveness and safety of improving depressive symptoms by applying tDCS for 6 weeks to patients with mild to moderate depression.
- Trial name
- NCT04720040
- Testing
- Mind STIM
- Where
- South Korea
- Volunteers
- 65 people
- Sponsor
- Ybrain Inc.
Depression, Major Depressive Disorder
Effect of SSRIs on Response to Psilocybin Therapy
This study is an open-label, single-arm, within-subjects design in individuals with mild-moderate Major Depressive Disorder (MDD). All participants will receive a single dose of 25mg of psilocybin in a therapeutic setting.
- Conditions
- Depression, Major Depressive Disorder, Mild Depression, Moderate Depression
- Trial name
- NCT05594667
- Testing
- Psilocybin
- Where
- Canada
- Sponsor
- Cybin Therapeutics Inc.
Depression - Major Depressive Disorder, Cognition Disorders in Old Age
Real-world Clinical Response to Trazodone in Italy, Poland, and Romania
TRACOMDD study is a study with the intention to describe the real-world use of trazodone and the clinical response in a sub-group of patients affected by Major Depressive Disorder and Mild Cognitive impairment, by collecting data…
- Trial name
- NCT07377682
- Where
- Poland
- Volunteers
- 120 people
- Sponsor
- Aziende Chimiche Riunite Angelini Francesco S.p.A
Alzheimer Disease, Mild Cognitive Impairment
Clinical Feasibility of Speech Phenotyping for Remote Assessment of Neurodegenerative and Psychiatric Disorders
The primary objective of the study is to evaluate the feasibility of eliciting continuous narrative speech in different neurodegenerative and psychiatric indications, using remote, self-administered speech tasks, as measured by…
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Dementia With Lewy Bodies, Dementia, Vascular
- Trial name
- RHAPSODY (NCT04939818)
- Where
- 2 sites in United Kingdom
- Volunteers
- 172 people, healthy volunteers welcome
- Sponsor
- Novoic Limited